- Home
- CBUS vs ENTX Comparison
CBUS vs ENTX Comparison
Compare CBUS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBUS | ENTX |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.5M | 74.7M |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CBUS | ENTX |
|---|---|---|
| Price | $3.35 | $1.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $20.00 | $10.00 |
| AVG Volume (30 Days) | ★ 539.1K | 171.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.27 | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | ★ $4,262,000.00 | $181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $99.13 | N/A |
| P/E Ratio | ★ N/A | $7.11 |
| Revenue Growth | ★ 134.56 | N/A |
| 52 Week Low | $1.09 | $1.00 |
| 52 Week High | $3.80 | $3.22 |
Technical Indicators
Market Signals| Indicator | CBUS | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.37 | 40.12 |
| Support Level | $1.34 | $1.00 |
| Resistance Level | N/A | $2.28 |
| Average True Range (ATR) | 0.37 | 0.13 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 76.69 | 7.69 |
Price Performance
Historical ComparisonAbout CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.